Glipox (Imatinib)

Glipox (imatinib) is indicated for the treatment of specific cancers where tyrosine‑kinase activity drives disease progression.

• Chronic myeloid leukemia (CML) in chronic, accelerated, or blast phases.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL) when approved.
• Gastrointestinal stromal tumor (GIST) that is unresectable or metastatic.
• Certain KIT‑mutated or PDGFRA‑mutated solid tumors as determined by a physician.
• Post‑operative adjuvant therapy for high‑risk GIST if clinically indicated.

Side effects of Glipox vary in frequency and severity; patients should be aware of both common and less frequent serious reactions.

Common

• Nausea, vomiting, or loss of appetite.
• Diarrhea or abdominal cramping.
• Fluid retention leading to peripheral edema.
• Fatigue or generalized weakness.
• Skin rash or mild itching.

Serious

• Severe liver injury indicated by jaundice or markedly elevated enzymes.
• Cardiac dysfunction such as decreased left‑ventricular ejection fraction.
• Hemorrhagic events or severe bleeding.

Before starting Glipox, clinicians evaluate several safety considerations to minimize risks and optimize therapy.

• Assess liver function; dose adjustment may be required in hepatic impairment.
• Monitor complete blood counts regularly for cytopenias.
• Evaluate cardiac status, especially in patients with pre‑existing heart disease.
• Use caution in pregnant or breastfeeding women; the drug is classified as pregnancy category D.
• Review concomitant medications that affect CYP3A4 metabolism.
• Adjust dose in patients with severe renal impairment if necessary.
• Counsel patients on the importance of adherence and regular monitoring.

Glipox interacts with several medicines; some combinations should be avoided while others require careful monitoring.

Avoid

• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which can markedly reduce imatinib exposure.
• Concurrent use with potent CYP3A4 inhibitors like ketoconazole or clarithromycin without dose adjustment.

Use with caution

• Antacids or proton‑pump inhibitors may affect absorption; separate dosing times if needed.
• Anticoagulants (e.g., warfarin) may increase bleeding risk; monitor coagulation parameters.
• Vaccines containing live attenuated organisms should be avoided due to potential immunosuppression.